REG - CVS Group plc - Transaction in Own Shares

CVSAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260601:nRSA3224Ga&default-theme=true

RNS Number : 3224G  CVS Group plc  01 June 2026

01 June 2026

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

 

Transaction in own shares

 

CVS announces that it purchased the following number of its ordinary shares of
0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG,
London Branch ("Berenberg"), in accordance with the terms of the share buyback
programme announced on 26 May 2026 (the "Share Buyback Programme").

 

 Date of purchases:                                   26/05/2026 - 29/05/2026
 Aggregate number of Ordinary Shares purchased:       190,027
 Lowest price paid per share (GBp):                   1,226.00
 Highest price paid per share (GBp):                  1,282.00
 Volume weighted average price paid per share (GBp):  1,256.08

 

CVS intends to cancel all of the purchased Ordinary Shares.

 

Following settlement of the above purchases and cancellation of the Ordinary
Shares purchased, CVS will have  69,967,157 Ordinary Shares in issue and
holds no Ordinary Shares in treasury.

 

The total number of voting rights in CVS is therefore 69,967,157 and this
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, CVS under the Financial Conduct Authority's
Disclosure and Transparency Rules.

 

Since the commencement of the Share Buyback Programme, the Company has
repurchased  190,027  Ordinary Shares in aggregate at a weighted average
price of 1,256.08 pence per share.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation), as it forms part of Retained EU Law as defined in the
European Union (Withdrawal) Act 2018, [a full breakdown of the individual
trades made by Berenberg as part of the Share Buyback Programme is attached to
this announcement].

 

http://www.rns-pdf.londonstockexchange.com/rns/3224G_1-2026-5-29.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/3224G_1-2026-5-29.pdf)

 

 Contacts
 CVS Group plc                                via FGS Global

 Richard Fairman, Chief Executive Officer

 Robin Alfonso, Chief Financial Officer

 Paul Higgs, Chief Veterinary Officer

 Charlotte Page, Head of Investor Relations

 FGS Global                                   +44 (0)207 251 3801

 Faeth Birch                                  cvsgroup@fgsglobal.com (mailto:cvsgroup@fgsglobal.com)

 Charlie Chichester

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is a leading provider of veterinary services, operating in the UK
and Australia, listed on the Main Market of the London Stock Exchange.  CVS
is focused on providing high-quality clinical services to its clients and
their animals, with outstanding and dedicated clinical teams and support
colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and
3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSPPUQAAUPQGQB



            Copyright 2019 Regulatory News Service, all rights reserved